Abstract 50P
Background
Breast Cancer is the most diagnosed cancer type worldwide and the second leading cause of cancer-related deaths among women. Anti-HER2 treatment has shifted the treatment paradigm of HER2-positive tumors. Historically, only breast cancer patients with HER2 IHC score of 3+ or with HER2 gene (FISH) amplification have benefited from anti-HER2 agents. However, emerging evidence suggests that even a minimal amplification of HER2 may significantly impact response to therapy and prognosis. This led to the introduction of the new concept of HER2-low breast cancers. Our retrospective analysis aims to unveil the impact of HER2 low expression on the response to neoadjuvant chemotherapy (NACT) in non-metastatic HER2-negative breast cancers.
Methods
All patients’ profiles with non-metastatic, HER2-negative breast cancers who received neo-adjuvant chemotherapy and underwent surgery between the 1st of January 2018 and the 30th of August 2022 were retrospectively reviewed. Patients were stratified into HER2-low and HER2-negative groups based on IHC score and FISH amplification. To compare the two study groups, patients’ response was clinically evaluated using surgical pathology reports. The primary endpoint was the response to NACT reported as the objective response rate (ORR) of HER2-low and HER2-negative tumors.
Results
Out of 262 patients, 236 patients had a response. Among the responders, 32 patients (14%) in the HER2-low group had a complete response compared to 4 patients (14%) in the HER2-negative group, OR 0.7 (95% CI:0.2 – 3), p-value= 0.6. While 132 patients (57%) and 17 patients (59%) had a partial response in the HER2-low and HER2-negative groups respectively, OR 0.7 (95% CI:0.2 – 2), p-value= 0.5. Across both groups, more patients with hormone-positive tumors had a response compared to hormone-negative tumors (p-value=0.01).
Conclusions
Preliminary results did not show any statistically significant impact of HER2 low expression on neoadjuvant chemotherapy response. Nonetheless, statistical significance was observed relative to hormone expression, in accordance with the published literature.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Research Center, Hamad Medical Corporation.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract